CAM
PYXS icon

Cormorant Asset Management’s Pyxis Oncology PYXS Stock Holding History

Cormorant Asset Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-272,537
Closed -$1.09M – 74
2023
Q1 		$1.09M Sell
272,537
-396,317
-59% -$792K 0.07% 64
2022
Q4 		$896K Sell
668,854
-1
-0% -$2 0.06% 67
2022
Q3 		$1.32M Buy
668,855
+1
+0% +$3 0.09% 64
2022
Q2 		$1.59M Hold
668,854
– – 0.12% 65
2022
Q1 		$2.7M Hold
668,854
– – 0.21% 59
2021
Q4 		$7.12M Buy
+668,854
New +$7.66M 0.42% 48

Other funds holding PYXS

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cormorant Asset Management's PYXS Position: Q2 2023 in Review

Cormorant Asset Management sold out of Pyxis Oncology (PYXS) in Q2 2023, closing a stake of 272,537 shares — an estimated $1.09M sold.

Cormorant Asset Management first reported a position in PYXS in Q4 2021 and held it in 6 quarters. The position peaked at $7.12M in Q4 2021. 48 funds tracked by Wall St. Rank hold PYXS as of Q2 2023.

  • Cormorant Asset Management reported no remaining Pyxis Oncology position as of Q2 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 272,537 Pyxis Oncology shares in Q2 2023, an estimated $1.09M.
  • Cormorant Asset Management first reported a position in Pyxis Oncology in Q4 2021 and held it in 6 quarters.
  • Cormorant Asset Management's Pyxis Oncology position peaked at $7.12M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.